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ABSTRACT 
Background/Aim: To investigate the impact of HDV infection on morbidity and mortality of 
patients. 
Patients/Methods: Retrospective study on 188 patients, included into a program of periodic 
surveillance until 2008. Demographic data, stage of liver disease, treatment efficacy, development of 
liver complications (ascites, oesophageal bleeding, encephalopathy), and survival  were registered. 
Cox regression analysis was carried out to determine the impact of viral and patient features on 
survival.  
Results: At baseline, 126 patients (67%) tested positive for serum IgM anti-HDV antibodies, 171  
(91%) for anti-HBe, 175 (91%) for serum HDV-RNA, and  61 (33%) for serum HBV-DNA.  Eighty-
two patients (43%) had chronic hepatitis at histology, the remaining 106  individuals a 
clinical/histological diagnosis of cirrhosis. Ninety-six patients received interferon (n=90), or  
lamivudine (n=6) therapy, and  27 of them (30%) attained a sustained response. During  follow up 
21 patients with chronic hepatitis progressed to cirrhosis. Of the 127 cirrhotic patients, hepatic 
decompensation occurred in 42 patients (33%),  and hepatocellular carcinoma in 17 (13%). The 5- 
and 10- year survivals free of  events were 96.8% and 81.9% for patients  with chronic hepatitis, and 
83.9% and 59.4% for cirrhotics (p<0.01). At multivariate analysis, no antiviral therapy (p=0.01),  
cirrhosis at presentation (p<0.01), and male sex (p=0.03) independently predicted a worse outcome.  
Conclusion: HDV liver disease lasts several decades. Half of patients who develop cirrhosis 
advances to liver failure. At present interferon therapy is recommended as soon as possible to slow 
or alter the  natural course of the liver disease.   
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
The hepatitis D virus (HDV) is a single stranded RNA virus that requires a helper function 
provided by the hepatitis B virus (HBV) for replication (1). Analysis of HDV isolates from different 
regions of the world revealed eight phylogenetically distinct genotypes. Distinct geographic 
distribution has become apparent, with genotype I being the most frequent (2). Moreover, the 
pathogenicity of HDV genotypes has been reported as highly variable (3). 
Since the 1990s, the circulation of HDV in several countries of the world has declined 
steadily, due essentially to the implementation of vaccine immunoprophylaxis against HBV, a 
strategy  that is depriving the defective HDV virus of the HBV network necessary to propagate its 
infection (4). In Europe this decline sustained the expectation that hepatitis D would be brought 
under control. However,  surveys in England (5), Germany (6), and Italy (7) have revealed the 
decline has not continued in most recent years, with a consistent reservoir of HDV remaining in 
immigrants from many parts of the world.  
Along with the substantial decline in the epidemiology of HDV, the clinical scenario of 
hepatitis D has also changed. The clinical perception of HDV infection is moving  from a severe, 
rapidly progressive disease leading to end-stage liver failure or hepatocellular carcinoma (HCC) in 
few years,  to a slowly progressive liver cirrhosis for which liver transplantation represents the 
ultimate therapeutic option (8). In Italy, over an observation period of up to 28 years, chronic HDV 
infection  evolved to cirrhosis in 30% of patients, with clinical decompensation  being the first 
dominant complication (9).  
 Although substantial advances have been made in the treatment of chronic viral hepatitis, 
therapy  for chronic hepatitis D is not yet satisfactory. In practice,  monotherapy with conventional 
or pegylated interferons remains the only available option and may achieve remission of disease in 
20-50% of cases depending on dosage and duration of treatment. However, the rate of HDV-RNA 
clearance remains unsatisfactory (10-13), and the capability  of treatment to change the course of 
disease remains unclear. Therefore, the identification of factors influencing the outcome could 
significantly improve the management of HDV chronic hepatitis. 
 We studied virologic patterns, influence of treatment, occurrence of major complications, 
and survival in a cohort of patients with chronic HDV infection, who were consecutively enrolled  
in a program of periodic surveillance. 
 
 
 
 
Patients and Methods 
Patients 
We investigated all patients with  HDV infection who were admitted to the Liver Units of  San 
Giovanni Rotondo and Turin, Italy, from 1991 to 2005 and who agreed to be entered into a program 
of surveillance. Patients were enrolled if they met the following criteria: (1) HBsAg-positive in 
serum,  (2) serum positive HDV antibodies (IgG-anti-HDV) for at least 6 months,  (3) chronic 
hepatitis or cirrhosis at  histological and/or clinical evaluation,  (4) no evidence of HIV co-infection, 
(5) alcohol intake of less than 40 g/day, and (6) absence of clinical and/or ultrasound signs  of 
hepatic decompensation or HCC. The length of time elapsed from the initial diagnosis of HDV 
infection to enrolment was also evaluated. 
 
Diagnosis of HDV infection 
The diagnosis of HDV infection relied on serum anti-HDV IgG and HDV-RNA detection in 
HBsAg carriers. Tissue HDAg staining was commonly performed by an immunofluorescence 
technique in liver tissue sections obtained by percutaneous biopsy. Two criteria were deemed 
necessary in order to define an active HDV infection:  detection of  HDV antigen (HDAg) in liver 
tissue and/or of  serum IgM-anti-HDV antibodies, and presence of HDV-RNA in blood.   
 
PCR Analysis of Viral Nucleic Acids 
Semi-quantitative detection of HDV-RNA in serum was performed as previously described 
(14) by single and nested PCR amplifications of a highly conserved region of the HDV genome, by 
using primers selected among genotype I of HDV. The amplified region corresponded to the C-
terminal portion of the hepatitis delta antigen (HDAg) coding region, and included the RNA editing 
site and the polyadenylation signal. The sensitivity of the PCR assays was approximately 1000 
genomes for single PCR, and 10 genomes for nested PCR. To avoid false-negative results, which 
might be consequent to genetic variability of HDV virions, a second region was amplified in 
negative samples. The second amplified region targeted the ribozyme region of the genome, shown 
as the most conserved region among different genotypes (15).  
Serum HBV-DNA levels were determined by a commercial quantitative PCR assay 
(Amplicor HBV Monitor Test, Roche Diagnostics, GmbH Mannheim, Germany), with a sensitivity 
threshold of about 400 copies/mL (78 UI/mL).  Before PCR-based assay became available, HBV-
DNA was detected by a sandwich capture hybridization assay (Digene Diagnostics) with a lower 
detection limit of 5 pg/ml (286.000 UI/mL). HCV-RNA was detected by standard amplification 
assay (TMA, Bayer Diagnostics, Tarrytown, NY, USA).  
Independently from serum levels, detectable HDV viremia  was assumed as indicative of an 
active HDV infection. For HBV-DNA, the conventional cut-off level of 2000 UI/ml  was used to 
identify active HBV infection (16). Active HCV infection was defined on the basis of serum HCV  
RNA values above 600 IU/ml (17).  
 
Other Laboratory and Virological Testing 
Routine serological tests, as serum alanine (ALT) and aspartate (AST) aminotransferase,  
direct and total bilirubin, albumin, prothrombin time, complete blood counts, and  α-fetoprotein  
were assessed by standard methods. Serologic markers of HBV, HDV, HCV, and HIV were tested 
by commercial enzyme immunoassays (Abbott Laboratories, North Chicago IL; Sorin  Biomedica, 
Saluggia, Italy; Ortho Diagnostic Systems, Raritan, NJ). 
 
Definition of Response to Treatment 
The virological response was defined as loss of serum HDV-RNA at the end of treatment 
(end-of-therapy virological response) or during the post-therapy follow-up (sustained virological 
response). Relapse was defined as reappearance of serum HDV-RNA after treatment. A biochemical 
response  was defined as normal serum alanine aminotransferase levels at end of treatment (end-of-
therapy biochemical response) or during follow-up (sustained biochemical response). A relapse was 
defined as an increase in serum alanine aminotransferase levels to more than 1.5 times the upper 
limit of normal after a biochemical response. 
 
Definition of Cirrhosis. 
Liver biopsy was proposed to define grading and staging of liver disease at enrolment and  
before antiviral treatment. Histological activity was evaluated by the modified Ishak score (18).  In 
patients who did not consent to liver biopsy, cirrhosis was diagnosed based on platelet count ≤ 
100,000 mm3, on ultrasound features of surface nodularity, splenomegaly, and portal vein diameter 
> 13 mm (19), and in detecting esophageal varices at endoscopy. Compensated cirrhosis was 
defined by  absence of ascites, jaundice, portal-systemic encephalopathy or variceal bleeding. 
Correspondingly, decompensated cirrhosis was defined as presence of any of these complications. 
 
Disease Progression 
In patients presenting with chronic hepatitis, progression to cirrhosis was defined by liver 
histology (F4) and/or platelet count, ultrasound and endoscopic features, as previously described. In 
those  presenting with cirrhosis, disease progression was evaluated by increased Child-Pugh class, 
development of clinical decompensation, or HCC. HCC was diagnosed based on the use of contrast 
imaging with computerized tomography (CT) scan, magnetic resonance imaging, and second 
generation contrast ultrasound. In patients undergoing liver biopsy, HCC was classified according 
to international criteria (20). Complications of cirrhosis such as ascites, jaundice, hepatic 
encephalopathy, and gastrointestinal bleeding were diagnosed and treated according to established 
criteria.  
 
  Statistical Analysis 
 Baseline characteristics and measures of clinical and demographic predictors (age, gender, 
etc.) are described as proportions or means and standard deviations. Separate Kaplan Meier survival 
analyses were presented for patients with chronic hepatitis and cirrhosis. Differences in survival 
times were assessed with a log-rank test. The effect of several risk factors on survival free of 
decompensation or HCC were evaluated by the Cox proportional hazards regression model. The 
results were expressed in terms of hazard ratios,  95% confidence intervals (CI), and Wald c 
statistics p values. All analyses were performed by using SPSS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS  
 
Baseline demographics and serologic/virological  profile of patients  
 One hundred and eighty-eight patients (56 females and 132 males) with a mean age of 50 +/- 
15 years represented the study population. Length of time elapsed from the initial diagnosis of HDV 
infection to enrolment into current investigation was 9.6 ± 7.5 years. Mean length of follow-up 
following the initial encounter  was 7.8 ± 4.1 years (range 3-17 years). All but 17 patients were of 
Italian descendent (140 from Southern Italy and 31 from Northern Italy); of non-Italian patients, 16 
were immigrants from Romania and one from Egypt. Eleven patients had at least one other relative 
included into the study. The route of HDV acquisition remained unrecognized in 96 patients (51%),  
but followed a blood transfusion  in 4 (2%), and was associated to intravenous drug use and 
multiple sexual partners in 24 (13%); of remaining patients, 62 (33%) recalled a family history of 
chronic HDV infection, and  2 (1%) a professional exposure (Table 1). 
Infection of HDV was diagnosed by serum HDV RNA detection in 175 patients (93%), with 
high (>1,000 copies/ml)  viremia levels in 120 of them;  in the remaining 13 non viremic  patients, 
the diagnosis relied on repeated anti-HDV positivity. All patients were infected by HDV genotype I 
and tested HBsAg positive; 17 (9%) patients were serum HBeAg positive, and  171 (91%) negative. 
Sixty-one patients (50 anti-HBe positive and 11 HBeAg positive) had detectable circulating levels 
of HBV-DNA, and in 50 of them with high (>2000 UI/ml) viremia  Eighteen patients tested positive 
for serum anti-HCV antibodies (Table 1), and 4 of them had also circulating HCV RNA. HCV 
genotype 3a was identified in 3 patients, genotype 1b in the remaining one. 
Table 1 reports demographic and clinical data of patients at baseline. Characteristics were 
not statistically different in patients with chronic hepatitis and cirrhosis. 
 The interrelationship between active HBV and active HDV infection, as apparent from 
serum viremia levels, is shown in Table 2. By taking as active HDV infection a serum HDV RNA 
level ≥10 genomes/ml, and as active HBV infection a serum HBV DNA level >2000 UI/ml, the two 
viruses appeared to be concomitantly replicating in 43 patients (23%), whereas HDV replication 
was shown capable to inactive HBV in 132 patients (70%); in only a minority of patients (4%) 
HBV replication inhibited HDV.  In the remaining 6 patients (3%) the two viruses were not 
detectable into the circulation.  
 
Histological and Clinical Diagnosis 
Liver histology was available for 108 patients and showed  mean inflammatory and fibrotic 
scores of 8.7 ± 2.9 (range 2-13) and 4.1 ± 1.3 (range 2-6), respectively. Of the remaining 80 patients 
who refused a liver biopsy, a  chronic hepatitis was clinically ascertained in 22 patients and a stable 
cirrhosis in the remaining 58 patients (Table 3).  
 
Treatment   
 Overall, 96 patients (51%) received antiviral treatment,  63 of them  were treated with 
conventional interferon at doses ranging from 6 and 9 million units thrice weekly for 12 months as a 
mean; 27 patients were treated with peg-interferon alpha 2b  at a dosage of 1.5 μg/kg weekly for 72 
weeks, given as monotherapy in 21 patients  or in combination with 800 mg daily of ribavirin in the 
remaining 6 patients;  6 patients received  lamivudine monotherapy at a dosage of 100 mg/day for 
12 or 24 months. Of the 90 interferon-treated patients, 61 (68%) were treated with a single course, 
26 (29%) underwent a second course of either standard interferon (19 patients) or pegylated 
interferon (7 patients),  and 3 patients  (3%) were treated with 3 courses (Table 4). Overall, 27 
patients (30%) attained a sustained response, 13 of 47 patients (28%) with chronic hepatitis at 
baseline, and 14 of 43 (33%) cirrhotics at enrolment. Among the 6 patients treated with lamivudine, 
all of them HBV-DNA and HDV-RNA positive at treatment start, no single patient experienced  
viral clearance during or after treatment. Ninety-two patients (49%) were never treated due to  
refusal (n=23, 25% of untreated), low platelet counts (n=41, 45%), or  persistently normal serum 
transaminases levels (n=28, 30%).   
 
Virological and clinical outcome  
 All patients were followed up for a mean of 7.8 ± 4.1 years ( range 3-17 years). The serum 
virologic profile of patients at the last evaluation is given in  Table 2: 109 patients  (58%) had 
virological profiles stabilized over time,  whereas in 79 patients the pattern of HDV and HBV 
viremia varied. At the last evaluation,  135 of 175 viremic patients at baseline tested HDV-RNA 
positive, whereas clearance of HDV viremia was documented in 40 patients, 72% of them with 
liver cirrhosis. HBV-DNA persisted positive in 19 out of 50 patients  with HBV-DNA levels  > 
2000 UI/ml at baseline.  Twelve patients (6%) lost serum HBsAg, 2 of them  had a spontaneous 
clearance, while in the other 10 subjects viral clearance followed interferon treatment. 
Seroconversion from HBsAg to anti-HBs was documented in 2 patients, with a title of anti-HBs of 
150 and 250 UI/ml, respectively, and persistently normal transaminases levels. 
The clinical sequelae of patients,  according to their fibrotic stage at presentation,  are shown 
in Fig. 1. Among the 82 patients with clinical, instrumental or histological features of chronic 
hepatitis at baseline, 61 subjects had a stable un-progressive disease at the last visit, and in the 
remaining patients the liver disease progressed to the stage of cirrhosis (Fig 1). The cumulative 
probability of developing cirrhosis among patients without the condition at baseline was 0.70 at 17 
years,  with an incidence rate of 1.23 per year. Male gender was identified as risk factor for 
cirrhosis development (p = 0.02).  One hundred and twenty-seven patients  had the HDV infection 
progressed to liver cirrhosis, 107 of them at presentation and the remaining 21 subjects  during the 
follow up.  When  initially recognized,   all cirrhotic patients were in Child-Pugh class A, whereas  
during the follow up,  8 patients progressed to class B,  and 51 to class C. At the last visit, 
esophageal varices were detected at endoscopy in 62 patients (49%). Forty-two cirrhotic  patients 
experienced one or several  episodes of liver decompensation, with a 0.75  cumulative probability 
of developing decompensation  at 17 years, and an incidence rate of complication  of 2.47 per year. 
Decompensated events included ascites (36 patients), jaundice (25 patients), bleeding from 
esophageal varices (9 patients),  and encephalopathy (12 patients). Seventeen cirrhotic patients 
developed a HCC, at a cumulative rate  of 0.55 at 17 years, and an annual incidence rate of 1.0.  At 
the diagnosis of  HCC, patients had a mean age of 53±13 years, were in the majority males (70%), 
with unknown risk of infection (70%), anti-HBe positive (82%) and persistent HDV-viremia (53%). 
HBV-DNA was detectable in 4 patients (viremia < 2000 UI/ml). 
 
Survival  
 At the end of follow-up 17 patients have died (9%). Causes of death were liver failure in 11, 
complications after OLT in 3 patients and liver-unrelated events in 3 (trauma in 1, sepsis after 
cholecystitis in 1, and malignancy in 1). One-hundred and seventy-one patients (91%) were still 
alive: 126 free of complications, 35 after OLT,  and 10 with signs of severe liver decompensation 
(n=3) or  HCC (n=7). Transplanted patients were followed for a mean period of 8 years ± 3.9 (mean 
± SD). In 6 of them malignancies were diagnosed (colon cancer in 2 patients, breast cancer in 1, 
HCC in 1, non-Hodgkin lymphoma in 1, cutaneous basocellular epithelioma in 1). In 4 patients 
biliary-plastic procedures were performed due to bilio-digestive anastomosis strictures.     
For the entire  cohort of patients, the median probability of surving  free of major events of 
liver decompensation or HCC from the initial diagnosis of  HDV infection was 28 years (Fig 2). 
The 5- and 10- year probabilities  of survival free of liver decompensation and of HCC were 96.8% 
and 81.9% for patients  with chronic hepatitis, and 83.9% and 59.4% for those with cirrhosis 
(p<0.01) (Fig 3). For the 96 patients who received a single or several courses of antiviral therapies, 
the 5- and 10- survival probabilities free of major complications were 95% and 88%.  
 
 
 
Prognostic factors of survival free of complications. 
At the univariate analysis, no antiviral therapy, cirrhosis and male sex resulted significantly 
associated with liver decompensation or HCC development (p<0.01). When significant and nearly 
significant predictors of worse outcome of disease were included in a multivariate analysis, 
cirrhosis (p<0.01,  HR 3.40 [IC  95% 1.60-7.22]), lack of treatment (p=0.01, HR 2.06 [IC 95% 
1.17-3.62]), and male gender (p=0.03 HR 1.93 [IC 95% 1.08-3.48])  resulted as independent 
predictors of an unfavorable outcome (Table 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
In the current study we evaluated the clinical course of a chronic HDV infection in a large 
cohort of patients followed up for a mean period of 8 years. The scrutinized  population was 
homogeneous for its origin (mostly from Southern Italy), the prevailing  HDV genotype (genotype  
I), and a low rate of  HBV replication. At presentation, the cohort included 82 patients (44%) with 
chronic hepatitis, a fourth of them evolving to cirrhosis during the observation period, and 106 
(56%) cirrhotics, half of them  developing major complications during the follow-up.  These data  
confirm the highly pathogenicity of HDV, and the prevalence of subjects with cirrhosis  among 
HDV carriers  referring to our  units (3). The identification of virological, therapeutic and/or host 
factors able to stabilize chronic hepatitis and to avoid decompensation and HCC remains a major 
issue. 
 Replicative activity of HDV and HBV may influence the course of disease (3, 21). At 
baseline HDV-RNA resulted positive in 91% of our patients, as tested by the semi-quantitative 
PCR, and viremia was detectable either in patients with chronic hepatitis and cirrhosis. Changes in 
HDV replication have been reported  during the follow up of  patients with  HDV chronic disease 
(9,15). In our series 40 patients cleared viremia, either spontaneously or after interferon therapy, 
and  2/3 of patients were cirrhotics. Previous observation would suggest that the earlier the HDV 
infection is cleared the more relevant would be the impact of viral clearance of the overall prognosis 
of the liver disease: once the stage of liver cirrhosis has developed, the viral clearance will have 
limited influence on further course of the liver disease. The dynamic inter-relationship between 
HDV and HBV requires  serial determinations  of viremia levels better define which of the two 
viruses might be responsible for the liver damage.  In agreement with a previous report (17), at the 
two time-points evaluated in the present investigation  viremia levels of the two viruses  fluctuated 
widely, an observation that could be related to either intrinsic mechanisms of reciprocal HDV-HBV 
inhibition or to  the variable progression of the underlying liver disease (21). Seroclearance of 
HBsAg in patients with HDV chronic infection represents the ultimate step in the process of HDV  
clearance (22). Indeed, as long as the HBsAg is produced, HDV can thrive and sustain replication 
and liver disease.  Twelve patients lost serum HBsAg (6%) in our cohort , and the clearance 
occurred mostly in patients with chronic hepatitis, and was favorably influenced by the  interferon 
therapy. 
 Our study showed that previous antiviral treatment with interferon  was significantly 
associated with a less aggressive outcome. The role of interferon therapy in patients with chronic 
HDV infection is controversial. Available trials indicate that high doses of  interferon  and a long 
duration of therapy were associated with biochemical response and improvement in liver histology 
(23). The implementation  of pegylated-IFN-α has substantially improved the pharmacokinetic and 
pharmacodynamic profiles of standard IFN-α and has provided better compliance for the long-term 
treatment required in chronic hepatitis D. Crucial challenges remain related to the selection of 
patients to treat, the definition of response and the duration of treatment. We suggest treatment with 
Peg-IFN at high doses for patients with compensated chronic hepatitis D as soon as diagnosis is 
made. Response should be evaluated based on decrease in serum of HDV-RNA and therapy should 
be continued for at least 1 year before a patient is defined as non responder. Moreover, regression of 
fibrosis and amelioration of clinical outcome has been reported in patients with sustained  benefit 
from therapy-induced HDV clearance. (24). In keeping with previous data (24),  the majority of our 
treated patients maintained a stable disease and only a minority of them  evolved toward liver 
decompensation or developed  HCC. Of interest, a favorable outcome was observed either in 
patients who cleared HDV viremia after interferon therapy and in those still  viremic at end of the 
study. In the last group of patients we are tempted to relate this favorable outcome to a reduction in 
HDV levels, which could not be quantified with available method.  
 We could confirm previous observations on a mild course of the HDV infection in the long 
run: overall, episodes of major live-related events of decompensation were observed in 42 (22%) of 
188 infected patients during the 8 years of follow-up. In addition,  the median survival free of major 
complications   was in direct relation with the underlying stage of the liver disease at baseline: 
ascites, gastrointestinal bleeding, encephalopathy and/or jaundice occurred in  37 (35%) out of 106 
cirrhotics. A recent study from Romeo et al. (9) reported at least one episode of liver 
decompensation in 54 of 299 patients under observation,  with a comparable percentage of 18%. 
Previously Fattovich et al. (25), analyzing a smaller cohort of patients, reported decompensation in 
12 of 39 (31%) HDV-positive cirrhotic patients.  
 Seventeen patients in our cohort (9%) were diagnosed with HCC , and 9 of them were 
transplanted. The mean age of these patients was 53±13 years and persistent HBV replication was 
observed in 29%.  Romeo et al. (9) diagnosed HCC in 46 out of 299 pts (15%) and reported  the 
chance of developing HCC to be influenced  by previous treatment with interferon and persistent 
HBV replication. The carcinogenetic role of HDV by itself remains unclear, mostly due to the 
powerful role of HBV and its ability to integrate into the host genome (affecting cellular signaling 
and growth control), but data concerning to the oncogenetic power of HDV by itself  are discordant. 
Indeed,  in areas where HBV-related HCC is endemic, such as Taiwan,  few cases of HCC have 
been related to an ongoing  HDV infection (26). On the contrary,  in Italy anti-HDV positive 
cirrhotics were reported at increased risk for HCC compared to anti-HDV negative patients. (25)   
HDV genotype I has been worldwide associated with a  highly pathogenic potential (3). In  
our area, where this genotype is almost exclusively represented (14),  a third of patients cleared the 
HBsAg  and maintained a preserved liver functional reserve; it is worth mentioning that 17% of 
patients with HBsAg clearance seroconverted to anti-HBs development during the long run.  
In conclusion, main finding of our study was the observation that interferon therapy 
modified the outcome of patients with chronic HDV-related liver disease by reducing the 
occurrence of major complications. In our cohort of patients, HCC was not the major complication, 
while ascites and gastrointestinal bleeding prevailed in drawing patients toward death and OLT. 
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TAB 1.  Demographic and clinical data of enrolled patients at baseline. 
 All Patients  Chronic Hepatitis Cirrhosis 
Chronic Hepatitis (no, %) 82 (44) 82 (44) NA 
Cirrhosis (no, %) 106 (56) NA 106 (56) 
Age (years mean ± SD) 50 ± 15 48 ± 16 51 ± 14 
Gender, male (no,%) 132 (70) 58 (70) 74 (70) 
Known Risk Factors of transmission (no,%) 92 (49) 44 (54) 48 (46) 
BMI (kg/m2 , mean ± SD) 26.3 ± 3.7 26.4 ± 3.6 26 ± 4 
Glycemia (mg%, mean ± SD) 93 ± 17 93 ± 21 93 ± 13 
ALT (mean ± SD) 116 ± 105 110 ± 86 107 ± 87 
Anti-HCV +ve (no, %) 18 (9.6) 6 (7) 12 (11) 
HDV-RNA +ve (no, %) 175 (93) 77 (94) 98 (93) 
HDV-RNA > 1000 genomes/ml  (no, %) 97 (52) 49 (60) 48 (45) 
HBV-DNA +ve (no, %) 61 (32) 31 (39) 30 (28) 
 
 
 
TAB 2. Distribution of 188 HDV/HBV-positive patients according to longitudinal virological profiles. 
 
Baseline                                               Last Observation 
 
 N°of Cases % Active HDV/ 
Active HBV 
Active HDV/ 
Inactive HBV 
Inactive HDV/ 
Active HBV 
Inactive 
HDV/HBV 
Active HDV/Active HBV 43 (23%) 10  25 - 8 
Active HDV/Inactive HBV 132 (70%) 4 94  1 33 
Inactive HDV/Active HBV 7 (4%) - - 2  5 
Inactive HDV and HBV 6 (3%) 1 1 1 3  
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Outcome according with stage of fibrosis at liver histology or clinical diagnosis at baseline. 
 Progression  
to Cirrhosis 
Alive with HCC or 
Decompensation  
OLT Death HBsAg 
Clearance 
Fibrosis at Liver Histology:    
    Ishak Score 0-2             N=13 
                        3-4             N=47 
                        5-6             N=48 
 
- 
21 
NA 
 
- 
1 
4 
 
- 
6 
 12 
 
- 
1 
5 
 
7 
2 
2 
Clinical Chronic Hepatitis  N=22 - - - - 1 
Clinical Cirrhosis               N=58  NA 5 20 5 0 
Total                                  N=188 21 10 38 11 0 
 
NA Not applicable 
 
 
 
 
 
 
 
 
Table 4. Outcome of untreated and treated patients either with Lamivudine or ≥ 1 cycle of Interferon.   
 Treatment Baseline 
CH 
Baseline  
Cirrhosis 
SVR HBs-Ag 
clearance 
Decomp. 
or HCC 
       
Treated Pts N=96 Lam MonoTx n=6 3 3 0 0 3 
 IFN 1 cycle    n=61 29 32 18 8 11 
 IFN > 1 cycle n=29 18 11 9 2 1 
Untreated Pts N=92             No 32  60 NA 2 44 
 
Table 5. Univariate and multivariate survival analysis of variables associated with outcome free of decompensation or 
HCC. 
 
 HCC or 
decompensated 
No HCC or 
decompensated 
Univariate 
Analysis 
Multivariate                     
Analysis 
  
Variables  n=59 n=129 p value p value HR 95% CI  
      Lower Upper 
Gender Male 42 90 0,05 0,03 1,93 1,08 3,48 
Age <=50 26 69 0,98 -    
Unknown Risk of 
Transmission 
34 62 0,56 -    
HCV 3 15 0,28 -    
HDV-RNA  
persistence 
37 98 0,60 -    
HBVDNA +ve  
at baseline 
19 42 0,79 -    
No Treatment 41 51 < 0,01 0,01 2,06 1,17 3,62 
Cirrhosis at  
Baseline 
51 55 < 0,01 < 0,01 3,40 1,60 7,22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE LEGENDS 
Fig 1.  Outcome of Patients with chronic hepatitis and cirrhosis at baseline. 
 
Fig 2. Overall survival free of major complications from the initial diagnosis of HBV/HDV           
co infection. 
 
Fig 3.  Probability of survival free of major complications according to staging of chronic hepatitis 
and cirrhosis at enrolment. Eight complications were observed  in patients with chronic hepatitis vs 
51 events in cirrhotic patients. 
 
Fig 4. Probability of survival free of major complications in treated patients.  
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